Hydroxychloroquine in Stage 1 Type 1 Diabetes

for the Type 1 diabetes TrialNet Study Group

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


OBJECTIVE Innate immune responses may be involved in the earliest phases of type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS To test whether blocking innate immaune cells modulated progression of the disease, we randomly assigned 273 individuals with stage 1 T1D to treatment with hydroxychloroquine (n = 183; 5 mg/kg per day to a maximum of 400 mg) or placebo (n = 90) and assessed whether hydroxychloroquine treatment delayed or prevented progression to stage 2 T1D (i.e., two or more islet autoantibodies with abnormal glucose tolerance). RESULTS After a median follow-up of 23.3 months, the trial was stopped prematurely by the data safety monitoring board because of futility. There were no safety concerns in the hydroxychloroquine arm, including in annual ophthalmologic examinations. Preplanned secondary analyses showed a transient decrease in the glucose average area under the curve to oral glucose in the hydroxychloroquinetreated arm at month 6 and reduced titers of anti-GAD and anti-insulin autoantibodies and acquisition of positive autoantibodies in the hydroxychloroquine arm (P = 0.032). CONCLUSIONS We conclude that hydroxychloroquine does not delay progression to stage 2 T1D in individuals with stage 1 disease. Drug treatment reduces the acquisition of additional autoantibodies and the titers of autoantibodies to GAD and insulin.

Original languageEnglish (US)
Pages (from-to)2035-2043
Number of pages9
JournalDiabetes care
Issue number11
StatePublished - Nov 2023

Bibliographical note

Publisher Copyright:
© 2023 by the American Diabetes Association.


Dive into the research topics of 'Hydroxychloroquine in Stage 1 Type 1 Diabetes'. Together they form a unique fingerprint.

Cite this